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Abstract
Background: Theory-based approaches are advocated to improve our understanding of prescription behaviour.
This study is an application of the theory of planned behaviour (TPB) with additional variables. It was designed to
assess which variables were associated with the intention to prescribe hormone therapy (HT). In addition,
variations in the measures across medical specialities (GPs and gynaecologists) and across countries (France and
Quebec) were investigated.
Methods: A survey among 2,000 doctors from France and 1,044 doctors from Quebec was conducted. Data
were collected by means of a self-administered questionnaire. A clinical vignette was used to elicit doctors'
opinions. The following TPB variables were assessed: attitude, subjective norm, perceived behavioural control,
attitudinal beliefs, normative beliefs and power of control beliefs. Additional variables (role belief, moral norm and
practice pattern-related factors) were also assessed. A stepwise logistic regression was used to assess which
variables were associated with the intention to prescribe HT. GPs and gynaecologists were compared to each
other within countries and the two countries were compared within the specialties.
Results: Overall, 1,085 doctors from France returned their questionnaire and 516 doctors from Quebec
(response rate = 54% and 49%, respectively). In the overall regression model, power of control beliefs, moral
norm and role belief were significantly associated with intention (all at p < 0.0001). The models by specialty and
country were: for GPs in Quebec, power of control beliefs (p < 0.0001), moral norm (p < 0.01) and cytology and
hormonal dosage (both at p < 0.05); for GPs in France, power of control beliefs and role belief (both at p < 0.0001)
and perception of behavioural control (p < 0.05) and cessation of menses (p < 0.01); for gynaecologists in Quebec,
moral norm and power of control beliefs (both at p = 0.01); and for gynaecologists in France, power of control
beliefs (p < 0.0001), and moral norm, role belief and lipid profile (all at p < 0.05).
Conclusion: In both countries, compared with GPs, intention to prescribe HT was higher for gynaecologists.
Psychosocial determinants of doctors' intention to prescribe HT varied according to the specialty and the country
thus, suggesting an influence of contextual factors on these determinants.
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Background
Until the results of the Women's Health Initiative trial [1]
were known, hormone therapy (HT) was promoted for
preventing osteoporosis and was thought to protect from
cardiovascular diseases [2]. Although physicians agreed
that menopause was not a disease, they considered it a
serious health problem [3]. Hot flashes, night sweats and
osteoporosis were reasons for gynaecologists and general
practitioners (GPs) to prescribe HT [4]. Notwithstanding
these benefits, breast cancer was a major concern [5,6].
Moreover, many women objected to adopting HT at men-
opause from fear of medicalization of an otherwise natu-
ral process [7]. Regardless of these conflicting evidences,
in Canada, at the time this study was conducted, Pre-
marin®, a known estrogenic compound, was the most pre-
scribed drug by gynaecologists and the third most
prescribed drug by GPs [8].
Following the Women's Health Initiative trial [1], there
was a decrease in the number of prescriptions of standard-
dose HT but a slight increase in the number of prescrip-
tions of low-dose HT in the United States [9]. In fact, HT
remains the most effective option to alleviate severe peri-
menopausal symptoms such as hot flashes [10]. Moreo-
ver, although HT is not a first-line treatment
recommended for preventing osteoporosis [11], its use is
associated with a decrease in fractures in current users
[12]. Based on the results of the Women's Health Initia-
tive trial, HT use for 1 year in 10 000 healthy postmeno-
pausal women is associated with 7 more cardiovascular
disease events, 8 more invasive breast cancers, 8 more
strokes, 8 more pulmonary emboli, 6 fewer colorectal can-
cers and 5 fewer hip fractures [1]. Weighing the benefits
with the risks associated with HT reminds women and
their doctor that deciding about HT requires a careful and
individualised assessment of their personal situation.
It is in this context that decisions about HT is said to be
representative of clinical decision-making in the face of
scientific uncertainty [13,14]. Thus, it is likely that many
factors play a role in a doctor decision-making process
leading to a prescription of HT. Attitude towards HT is
associated with the medical specialty [15,16], and age [17]
as well as gender of the provider [15,18]. The country in
which a doctor practices medicine also appeared to play a
role [19].
Conceptual underpinnings of this study
In studies of doctors' decision-making and related pre-
scription behaviours, more attention needs to be given to
the use and combination of different theories [20]. The
lack of use of theories restrains effective implementation
of change in patients' care because it restrains our under-
standing of the pathways through which a given imple-
mentation strategy is effective. The theory of planned
behaviour [21] is well known through its previous appli-
cations to the study of doctors' behaviours [22-25]. This
theory provides a theoretical account of the way in which
attitude, subjective norm and perceived behavioural con-
trol combine to predict a given behavioural intention
(decision-making) [26] and in turn, a given behaviour
[27]. Thus, it provides direction for elaborating effective
strategies that will influence the decision-making process
leading to change in doctors' behaviours.
This theory postulates that under a controlled situation,
intention is the immediate determinant of behaviour
[21]. In turn, this intention is under the influence of three
main factors: attitude, subjective norm and perceived
behavioural control. Each can be assessed directly or indi-
rectly (beliefs-based measure). Attitude is conceptualized
as a personal evaluation of the action. It is the product of
a set of salient beliefs about the consequences of perform-
ing the behaviour, each weighted by an evaluation of the
importance of the respective consequences. Subjective
norm refers to a perceived social pressure to perform the
behaviour in question. The belief-based measure requires
that the individual's normative beliefs be multiplied by
the individual's motivation to comply with these socially-
normative referents. Perceived behavioural control is a
measure of the amount of control the individual has over
the behaviour in question. It refers to the individual's per-
ception of barriers or facilitating factors likely to influence
the adoption of the behaviour. It can also be measured
directly or indirectly. For the indirect measurements, the
individual's control beliefs must be weighted by the corre-
sponding perceived evaluation of how much each of these
control beliefs will impact on the adoption of the behav-
iour. According to the authors of this theory, sociodemo-
graphics and other variables will influence behaviour
through their influence on the attitude, the subjective
norm and the perceived behavioural control [21]. Success-
ful behavioural change will occur only if the underlying
determinants of intention change.
Although the theory of planned behaviour has proven
useful when studying health related behaviours, two sys-
tematic reviews found that components of this theory
explain on average 41% of the variance in intention and
28% to 31% of the variance in behaviour thus, suggesting
that other variables must play a direct role on the behav-
ioural intention and possibly, on the behaviour itself
[28,29]. Consequently, some authors have expanded the
theory of planned behaviour to include other relevant
psychosocial constructs [28]. For example, the measure of
moral norm [30] was found to be useful in understanding
women's intention to use HT [31,32]. Moral norm takes
into account feelings of personal responsibility regarding
adoption of a specific behaviour, that is, the individual's
perception of the moral correctness or incorrectness ofBMC Medical Informatics and Decision Making 2005, 5:31 http://www.biomedcentral.com/1472-6947/5/31
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Initial theoretical model Figure 1
Initial theoretical model.
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performing the behaviour. Because of the potential influ-
ence of the medical specialty, in this study, role belief was
also taken into consideration [30]. Role belief refers to the
perception by the individual that members of a specific
group would perform the behaviour under study. The ini-
tial theoretical model adopted as a basis for examining the
psychosocial determinants associated with doctors' inten-
tion to prescribe HT is presented in Figure 1.
To our knowledge, at the time this study was planned, we
were not aware of any studies that had applied the theory
of planned behaviour to study variations of doctors'
intention to prescribe HT across countries. Physicians in
France and the province of Quebec, Canada, share the
same language (French) but use it in very different geo-
graphical and cultural settings. Therefore, studies of their
intention to prescribe HT offered a unique opportunity to
provide more insight in the cultural variation in the psy-
chosocial determinants associated with this behaviour
without the difficulties associated with having question-
naires in two different languages. Therefore, this study is
an application of the theory of planned behaviour with
additional variables. It was designed to assess which vari-
ables were associated with the intention to prescribe HT.
Hypotheses refer mainly to the assumption underlying
the theoretical framework. It could nonetheless be added
that we hypothesized that variations in the intention to
prescribe HT between gynaecologists and GPs would be
observed as well as variations in the intention to prescribe
HT between French and French Canadians physicians
would be observed.
Methods
Population and sampling strategy
The study was conducted in 1997 in France and in the
province of Quebec, Canada, where French is the promi-
nent language. In France, questionnaires were mailed to a
representative sample of 1,000 GPs and 1,000 gynaecolo-
gists, randomly drawn from an exhaustive list of 65,000
GPs and 7,000 gynaecologists. This daily updated list was
provided by Fournier Pharma, a French pharmaceutical
company that is known to have one of the most exhaus-
tive lists of physicians. This list is used for visiting physi-
cians in France. In Quebec, questionnaires were mailed to
all gynaecologists (n = 244) and to a representative sam-
ple of 800 GPs from an estimated pool of 7000 GPs. This
second list was provided by the medical licensing body of
this Canadian province.
Data collection procedure and development of the 
questionnaire
Data were collected by means of a mailed self-adminis-
tered questionnaire using a modified Dillman strategy
[33]. The development of the questionnaire was per-
formed in both France and Quebec to provide only one
questionnaire. The self-administered questionnaire com-
prised two sections. The first section addressed sociode-
mographics as well as self-reported practice patterns in the
field of menopausal health. The second section assessed
the behavioural intention of physician to prescribe HT
when faced with a clinical vignette. This clinical vignette
was developed in a series of two iterative consultations
and tested with a total of 22 GPs and 22 gynaecologists in
both countries. It presented a 55 years old menopausal
woman who had been menopausal for the past three
years. She had no specific opinion about HT and did not
complain about hot flashes. This woman had no contra-
indication to HT. She had no known risk factors for cardi-
ovascular disease or for osteoporosis. She had a 5-year risk
of breast cancer of 2% because her maternal grandmother
and her own mother suffered from breast cancer (average
risk = 1.5%) [34]. This clinical vignette was purposely
designed to maximize the variance in the intention of
physicians to prescribe HT.
Measures
Direct measures
In line with the theory of planned behaviour, the behav-
iour under study was defined as followed: to prescribe
(action) HT (target) to a menopausal woman who is con-
sulting for a routine periodical medical exam and who is
presented in the clinical vignette (context) [21]. The time
frame was not specified. Intention to prescribe HT was
assessed by means of two items. After the general com-
ment "If you were the physician of Mrs. X, what would
you do?", physicians were asked to answer the following
questions on a bipolar 7-point scale: "My intention would
be to prescribe her HT." ('unlikely' to 'likely'); "I would
prescribe her HT." ('disagreeing' to 'agreeing'). The mean
of the composite score was computed (Pearson r = 0.84).
Attitude was assessed by means of four items using a
semantic differential bipolar 7-point scale. The four pairs
of adjectives used were: "not gratifying/gratifying", "not
satisfying/satisfying", harmful/harmless" and "not useful/
useful". Each pair of adjectives appeared after the sen-
tence: "For me, prescribing HT for Mrs. X would be ...".
The mean composite score of the four items was taken as
the attitude value (Cronbach α = 0.90). Subjective norm
was assessed by means of two items, each assessed on a
bipolar 7-point scale. Physicians were invited to indicate
their level of agreement with the following statements:
"Most of the persons who are important for me in the pro-
fession would recommend that I prescribe HT to Mrs. X ",
('disagree' to 'agree'); "The proportion of my colleagues
who would prescribe HT to Mrs. X is ..." ('low' to 'high').
These two items were used to compute a mean composite
score (Pearson r = 0.84). Two items were included to
assess perceived behavioural control, each on a bipolar 7-
point response scale. The items were: "I see no barriers to
prescribing HT to Mrs. X " ('disagree' to 'agree'); "For me,BMC Medical Informatics and Decision Making 2005, 5:31 http://www.biomedcentral.com/1472-6947/5/31
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prescribing HT to Mrs. X would be..." ('difficult' to 'easy').
These two items were used to compute a mean composite
score (Pearson r = 0.79). Moral norm was obtained by
means of three items, each on a bipolar 7-point response
scale: "Given my personal convictions, I would prescribe
HT to Mrs. X" ('disagree' to 'agree'); "If I were to prescribe
HT to Mrs. X, I would feel guilty" ('agree' to 'disagree');
and "I think that this is totally ethical that I prescribe HT
to Mrs. X" ('disagree' to 'agree'). A mean composite score
for moral norm was computed (Cronbach α = 0.87). Role
belief was obtained by means of two items, each on a
bipolar 7-point response scale: "In a situation like the one
of Mrs. X, I think that a physician who has the same edu-
cation as me would prescribe HT" ('disagree' to 'agree');
and "In a situation like the one of Mrs. X, I think that a
physician of the same gender as me would prescribe HT"
('disagree' to 'agree'). The mean composite score reliabil-
ity value for moral norm was 0.87 (Pearson r).
Indirect measures
In line with methodological developments in the use of
the theory of planned behaviour, only one arm of each
indirect measure of the main constructs (attitude, social
norm and perception of control) was assessed, that is atti-
tudinal beliefs, normative beliefs and power of control
beliefs [35]. Therefore, no multiplicative procedure was
applied [36]. Attitudinal beliefs were assessed by means of
six items, each on a bipolar 7-point response scale ('disa-
gree' to 'agree'). Following the statement, "If I were to pre-
scribe HT to Mrs. X", physicians were asked to answer if
HT would: "reduce bone mass loss", "protect from cardio-
vascular diseases", "not raise significantly her risk of
breast cancer", "reduce completely her hot flushes", "pre-
vent ageing of the urogenital tract" and "improve her
breast exam follow-up". These six items were used to com-
pute a mean composite score for attitudinal beliefs (Cron-
bach α = 0.74). Normative beliefs were assessed with six
items, each on a bipolar 7-point response scale ('would
not approve' to 'would approve'). Individuals or groups
evaluated were: specialists of breast cancer, family mem-
bers of Mrs. X, rheumatologists, gynaecologists, cardiolo-
gists and physicians in general (Cronbach α = 0.89).
Power of control beliefs were assessed with six items pre-
sented as follows: "Even if ..., ("Mrs. X has no opinion on
HT", "results from the bone mass densitometry are not
available", "HT is medicalising menopause", "Mrs. X has
not many hot flushes", "Mrs. X has a family history of
breast cancer" and "Mrs. X has no risk factors for cardio-
vascular diseases") I would prescribe HT". These items
were assessed on a bipolar 7-point scale ('disagree' to
'agree'). These six items were used to compute a mean
composite score for power of control beliefs (Cronbach α
= 0.96).
For above variables, the bipolar 7-point scale was rated
numerically from -3 to +3. Therefore, a positive score indi-
cated that the physician expressed a positive evaluation of
the belief-based construct. Finally, sociodemographics
and practice patterns-related variables were assessed with
closed-ended questions [37]. Examinations performed
variables were assessed with a check list and included ele-
ments of the physical examination (for example, breast
and pelvic examination) and laboratory (for example,
lipid profile) as well as imaging investigations (for exam-
ple, mammography) that were relevant for a middle-aged
woman undergoing a routine periodical medical exam.
Data analysis
Descriptive analyses to assess the distribution of all the
explanatory variables were performed. They all showed a
near normal to normal distribution. Some elements in the
theory of planned behaviour constructs had missing
information. If less than one third of the responses were
missing for a given construct, then the mean of the other
responses within the construct was used to impute these
missing answers, otherwise the subject was considered as
having too many missing data and was not included in
the analysis. The means and SD of psychosocial variables
were analyzed by medical specialty and by country using
Student's t-test with the Bonferronni correction for multi-
ple group comparisons. A U-shaped distribution of the
dependant variable that is, the intention to prescribe HT
was observed (Figure 2). This type of distribution was not
amenable to a transformation. For further analysis, in line
with the theory of planned behaviour, the intention to
prescribe HT was dichotomized as follows: mean scores of
Distribution of the intention to prescribe HT Figure 2
Distribution of the intention to prescribe HT.
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1 and more were classified as high intention, whereas
mean scores of less than 1 were classified as low intention.
Multiple logistic regression analysis was used to deter-
mine factors associated with high intention.
First, an overall model (all doctors) was produced. Then,
doctors were grouped according to their specialty and
country of origin. Intention to prescribe HT was first
regressed on the direct measure of the main constructs of
the theory of planned behaviour (attitude, subjective
norm and perceived behavioural control). Second, role
belief, moral norm and power of control beliefs were
added to the variables retained in the model. Third, attitu-
dinal beliefs and normative beliefs were added. Last, only
if they were significant at a p of 0.20 or less in a bivariate
analysis with intention to prescribe HT, variables that
Table 1: Characteristics of participating doctors by country and medical specialty
Quebec France
General Practitioners 
n = 334 (%)
Gynaecologists 
n = 130 (%)
General Practitioners 
n = 425 (%)
Gynaecologists 
n = 586 (%)
Women 140 (42%) 35 (27%) 98 (23%) 316 (54%)
Age (years) 41.5 ± 8.6 47.4 ± 10.8 43.7 ± 7.6 45.4 ± 8.3
Number of years in practice
<8 years 82 (25%) 31 (24%) 109 (26%) 107 (18%)
9 – 15 years 92 (27%) 20 (15%) 116 (27%) 236 (40%)
16 – 21 years 90 (27%) 28 (21%) 125 (29%) 124 (21%)
>22 years 70 (21%) 51 (39%) 75 (18%) 119 (21%)
Rural place of practice 88 (27%) 8 (6%) 162 (38%) 55 (9%)
Number of patients/day*
<10 19 (6%) 6 (5%) 15 (4%) 42 (7%)
10 – 20 95 (29%) 20 (15%) 170 (40%) 299 (52%)
20 – 40 191 (58%) 83 (64%) 221 (53%) 224 (39%)
>40 24 (7%) 21 (16%) 14 (3%) 15 (2%)
% of menopausal patients in clientele 29.1 ± 25.0 56.0 ± 24.8 21.4 ± 20.2 50.5 ± 27.3
% who use menopausal diagnostic criteria**
Symptoms 118 (35%) 64 (49%) 174 (41%) 290 (49%)
Hormonal dosages 101 (30%) 23 (18%) 126 (30%) 173 (30%)
Cessation of menses 227 (68%) 78 (60%) 268 (63%) 328 (56%)
Discuss HT with all menopausal patients 122 (38%) 66 (51%) 101 (24%) 355 (61%)
Examinations performed**
Cytology (PAP smear) 292 (87%) 129 (87%) 363 (85%) 519 (89%)
Mammography 288 (86%) 120 (92%) 381 (90%) 578 (99%)
Breast examination 306 (92%) 127 (98%) 377 (89%) 580 (99%)
Hormonal dosages 113 (34%) 17 (13%) 139 (33%) 152 (26%)
Lipid profile 245 (73%) 59 (45%) 349 (82%) 387 (66%)
Endometrial biopsy 3 (1%) 16 (12%) 11 (3%) 40 (7%)
Bone mass density 30 (9%) 16 (12%) 84 (20%) 77 (13%)
Vaginal ultrasound 1 (0,3%) 4 (3%) 21 (5%) 158 (27%)
Thyroid gland examination 251 (75%) 61 (47%) 187 (44%) 156 (27%)
Pelvic examination 270 (81%) 126 (97%) 307 (72%) 569 (97%)
Speculum 272 (81%) 126 (97%) 276 (65%) 570 (97%)
Blood pressure 308 (92%) 119 (92%) 391 (92%) 569 (97%)
Cardiac auscultation 285 (85%) 29 (22%) 363 (85%) 148 (25%)
Weight 257 (77%) 58 (45%) 341 (80%) 505 (86%)
HT prescription patterns > 70% of cases 106 (34%) 86 (67%) 36 (9%) 309 (55%)
* Total number of doctors within the subgroup might differ from total number of participating doctors because of missing data.
** Categories are not mutually exclusive.BMC Medical Informatics and Decision Making 2005, 5:31 http://www.biomedcentral.com/1472-6947/5/31
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were external to the initial theoretical model (sociodemo-
graphics and practice patterns-related variables) were
tested. Adjusted odds ratio and their 95% confidence
intervals were computed. All reported p values were two-
sided. No interaction term was tested. The Statistical Anal-
ysis System (SAS Institute, Cary, NC) was used for data
analysis. This study was approved by the Ethics Commit-
tee of the University Centre where it was conducted.
Results
Characteristics of respondents
Overall, 1,085 French doctors returned their question-
naire (response rate = 54%) and 516 doctors from Quebec
(response rate = 49%). However, due to missing data,
1011 questionnaires from France (425 GPs and 586
gynaecologists) and 464 questionnaires from Quebec
(334 GPs and 130 gynaecologists) were analyzed. A larger
proportion of the respondents were gynaecologists in
France when compared with respondents in Quebec (58%
versus 28%). This difference was due to the different GPs/
gynaecologists ratio in the two samples invited to partici-
pate in each country: half of the doctors in the France sam-
ple were gynaecologists compared with 23% in the
Quebec sample. In France, as in Quebec, respondents
were significantly more likely to be women (in France
41% of the respondents and 33% of the nonrespondents,
p < 0.01; in Quebec 37% of the respondents and 31% of
the nonrespondents, p < 0.05). Characteristics of the par-
ticipants are presented in Table 1.
Means and standard deviation (SD) of the psychosocial 
variables by medical specialty and by country
Table 2 summarizes the means and standard deviation
(SD) of the psychosocial variables. In France, compared
with GPs, measures of all the psychosocial variables were
higher for gynaecologists (all at p  < 0.01). In Quebec,
compared with GPs, measures of the following psychoso-
cial variables were higher for gynaecologists: intention to
prescribe HT (p < 0.05) and attitude, subjective norm, per-
ceived behavioural control and moral norm (all at p <
0.01). Compared with gynaecologists from Quebec, those
from France showed a higher score for attitudinal beliefs
(p < 0.01). There were no differences between GPs from
France and those from Quebec.
Psychosocial factors associated with the intention to 
prescribe HT
The results of the regression analysis are presented in
Table 3. In the overall model (all doctors), three psycho-
social variables were associated with high intention:
power of control beliefs, moral norm and role belief (all
at p < 0.0001). Since neither the country of origin nor the
specialty was found statistically significant in this overall
model, and because of the difference in distribution of
these factors, separate models were prepared to assess the
variables associated with intention to prescribe HT for
each of the four combinations. For GPs from Quebec, two
psychosocial variables were associated with high inten-
tion: power of control beliefs (p  < 0.0001) and moral
norm (p < 0.01). Two variables that were external to the
initial theoretical model were also retained in the final
model: cytology and using hormonal dosage as a meno-
pausal criterion (both at p < 0.05). For GPs from France,
three psychosocial variables were associated with high
intention: power of control beliefs (p  < 0.0001), role
belief (p < 0.0001) and perceived behavioural control (p <
0.05). One variable that was external to the initial theoret-
ical model was added to the final model: using cessation
of menses as a menopausal criterion (p < 0.01). For gynae-
cologists from Quebec (n = 129), two psychosocial varia-
Table 2: Means and standard deviation (SD) of the psychosocial variables by medical specialty and by country
Quebec France
Psychosocial constructs General Practitioners 
n = 334
Gynaecologists 
n = 130
General Practitioners 
n = 425
Gynaecologists 
n = 586
Intention 0.030 ± 2.121 0.642 ± 2.086* -0.195 ± 2.216 0.556 ± 2.083**
Attitude 0.450 ± 1.456 0.951 ± 1.456** 0.265 ± 1.678 0.847 ± 1.492**
Subjective norm 0.026 ± 1.626 0.594 ± 1.641** -0.220 ± 1.621 0.316 ± 1.665**
Perceived behavioural control 0.053 ± 1.800 0.740 ± 1.721** -0.254 ± 1.929 0.560 ± 1.921**
Role belief 0.180 ± 1.809 0.535 ± 1.706 0.102 ± 1.821 0.521 ± 1.729**
Moral norm 0.585 ± 1.771 1.269 ± 1.671** 0.281 ± 2.037 0.963 ± 1.784**
Power of control beliefs 0.195 ± 1.960 0.614 ± 1.974 -0.041 ± 2.143 0.607 ± 2.057**
Behavioural beliefs 1.301 ± 0.975 1.525 ± 0.965 1.374 ± 1.061 1.963 ± 0.819**¶
Normative beliefs 0.438 ± 1.396 0.506 ± 1.223 0.287 ± 1.445 0.615 ± 1.270**
Statistical significance given after Bonferroni correction for multiple comparisons:
* p < 0.05 between General practitioners and Gynaecologists for each country
** p < 0.01 between General practitioners and Gynaecologists for each country
¶ p < 0.01 between Gynaecologists between countriesBMC Medical Informatics and Decision Making 2005, 5:31 http://www.biomedcentral.com/1472-6947/5/31
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bles were associated with high intention: moral norm (p <
0.01) and power of control beliefs (p < 0.01). No variables
that were external to the initial theoretical model were
added to this final model. For gynaecologists from France
(n = 577), three psychosocial variables were kept in the
final model: power of control beliefs (p < 0.0001), moral
norm (p < 0.05), role belief (p < 0.05). One variable that
was external to the initial theoretical model was added to
the final model: performing a lipid profile (p < 0.05).
Discussion
To our knowledge, this is the first study that adopted the
theory of planned behaviour as a theoretical basis for
assessing and comparing the psychosocial determinants
of GPs and gynaecologists' intention to prescribe HT in
two countries, France and in Quebec. To our knowledge,
this is also one of the few studies to adopt the theory of
planned behaviour for identifying factors that influence
doctors' behavioural intention to prescribe a medication
in the context of preference-sensitive care.
The results of this study indicated that doctors' intention
to prescribe HT varied according to their specialty. In both
countries, gynaecologists showed higher intention to pre-
scribe HT than GPs. This is in line with the results reported
by Hovi and colleagues who assessed Estonian and Finn-
ish GPs and gynaecologist opinions and prescribing prac-
tices in HT [19]. However, this intention did not vary
significantly between GPs in France and those in Quebec,
nor did it between gynaecologists in France and those in
Quebec.
In the overall model (for all physicians in both countries),
perceived barriers to prescription of HT was found to be
the most important determinant of the intention to pre-
scribe HT. This means that the more confident a doctor
was regarding his/her ability to counter the perceived bar-
riers that were assessed in this study, the more likely he/
she was to express a high intention to prescribe HT. This
is congruent with the observation made previously that a
significant proportion of physicians considered meno-
pause to be a serious health problem that needed to be
treated [3]. In other words, even in the absence of a clear
indication to prescribe HT (for example, severe hot
flashes) or a clear indication by a woman that she would
like to use HT, at that the time this study was conducted,
some physicians had high intention to do so.
Table 3: Psychosocial factors and other variables predicting intention to prescribe HT
Quebec and France Quebec France
All doctors 
N = 1472
General Practitioners 
N = 333
Gynaecologists 
N = 129
General Practitioners 
N = 419
Gynaecologists 
N = 577
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
TPB Constructs
RB 2.08**** (1.61 – 2.69) - - 4.60**** (2.17 – 9.73) 1.47* (1.03 – 2.11)
MN 2.38**** (1.70 – 3.34) 3.42** (1.52 – 7.66) 84.58** (3.64 – 4.00) - 1.75* (1.11 – 2.77)
PBC - - - 1.65* (1.07 – 2.55) -
Power of control beliefs 
(POC's)
4.92**** (3.51 – 6.90) 21.92**** (6.86 – 70.05) 15.86** (1.97 – 128.23) 5.80**** (3.05 – 11.03) 6.20**** (3.63 – 10.59)
Other Variables
Cytology (PAP smear) - 11.05* (1.01 – 123.08) - - -
Hormonal dosage as 
menopausal criteria
- 4.36* (1.15 – 16.50) - - -
Cessation of menses as 
menopausal criteria
- - - 4.44*** (1.45 – 13.59) -
Lipid profile - - - - 2.64* (1.23 – 2.68)
Likelihood Ration X2 
= 1580; degrees of 
freedom = 3; p < 
0.0001
Likelihood Ration X2 = 
384; degrees of freedom 
= 4; p < 0.0001
Likelihood Ration X2 = 
153; degrees of 
freedom = 2; p < 
0.0001
Likelihood Ration X2 = 
477; degrees of 
freedom = 4; p < 
0.0001
Likelihood Ration X2 = 
584; degrees of 
freedom = 4; p < 
0.0001
Note: Due to incomplete information in some sections of the questionnaire, 996 questionnaires from France (419 general practitioners and 577 
gynaecologists) and 462 questionnaires from Quebec (333 general practitioners and 129 gynaecologists) were used in the regression analysis. The 
differences in the total numbers of subjects in the regressions are due to missing information for some of the explanatory variables in the subgroup 
models. The outcome variable in the regressions is a dichotomous variable representing high vs. low intention to prescribe.
OR: Odds ratio; 95% CI: 95% Confidence Interval
* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001BMC Medical Informatics and Decision Making 2005, 5:31 http://www.biomedcentral.com/1472-6947/5/31
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Moral norm was found to be the second most important
determinant. In this study, moral norm was assessed with
three items referring to the physician's personal
convictions, sense of guilt and ethics. In the past, moral
norm was found to be the strongest predictor of women's
intention to adopt HT over a period of one year [32].
However, to our knowledge, the present study is one of
the first to document that moral norm is associated with
a doctor's prescription behaviour of HT. This means that,
in this context, doctors' most profound personal values
might overcome those of the women. As reported before
by Hoffmann and colleagues, this suggests that doctors
might be inclined to promote their own decision [38]. On
one hand, this is in line with the literature that points to
the contribution of doctors' preferences on the unex-
plained practice variation observed in the medical com-
munity [39]. On the other hand, this is contrary to the
growing social trends in regards with shared decision-
making [40]. Shared decision-making is grounded in eth-
ics in which a deliberative model of decision-making is
advocated [41]. A deliberative model of decision-making
recognizes that both protagonists are competent individ-
uals. It refers to the concepts of autonomy and self deter-
mination which underline the obligation of health care
providers to provide information [41]. Shared decision-
making emphasizes the importance of agreement on the
treatment option by the patient and the physicians as a
"the test of a shared decision" because "mutual acceptance
... remains a necessary prerequisite for shared decision-
making" [42]. Shared decision-making rests on the best
evidence of the risks and benefits of all the available
options and takes into account the establishment of a
context in which the values and preferences of the patient
are sought and his opinions valued [40]. Therefore, these
results suggest a need for interventions that will facilitate
the inclusion of the specific characteristics and values of
the patient in the decision. In the overall model, the inten-
tion to prescribe HT was also under the influence of role
belief. This means that intention to prescribe HT was
determined by a sense of belonging to a specific group
and how one ought to act accordingly. This is different
from the influence of subjective norm, which refers to per-
ceived social pressure to perform a specific behaviour. In
other words, doctors' intention to prescribe HT was
dependent on what they believe someone like them
should do. Doctors attach a high value to their clinical
autonomy, which is viewed by certain critics as a major
barrier to changing doctors' behaviour [43]. The positive
influence of role belief in predicting doctors' behaviour
had been reported before in the area of technology of
information [24]. It appears that in the context of HT pre-
scription, doctors might not be influenced by what others
would want them to do (including a specific patient), but
rather by what they believe a doctor like themselves ought
to do.
When specific regression models were built by medical
specialty and country, power of control beliefs was kept in
all models. Moral norm was kept in three out of the four
models: GPs in Quebec and gynaecologists in France and
in Quebec. Role belief was kept in both models from
France: GPs and gynaecologists, but not in the models of
doctors from Quebec (GPs and gynaecologists). This sug-
gests that, notwithstanding the medical specialty, there
might be differences between doctors from France and
those from Quebec regarding this particular behaviour.
In three out of the four models, variables that were exter-
nal to the initial theoretical model made a statistically sig-
nificant contribution. All of these variables pertained to
diagnostic testing. For example, in each of the regression
models pertaining to GPs' behavioural intention,
variables associated with diagnosing menopause were
found. This suggests that GPs in Quebec and in France
might need reassurance in the final objective diagnosis of
menopause before embarking on a prescription of HT.
Interestingly, attitude and attitudinal beliefs were not
retained in any of the regression models. This means that
the intention of doctors to prescribe HT was not under the
influence of those doctors' personal evaluation of this
action (for example, the consequences of prescribing HT
on the woman's health outcomes). This suggests that,
when controlled for other psychosocial variables, the pre-
scription of HT was not under the influence of what doc-
tors believe HT would have had as potential benefits or
risks to this woman.
Another interesting finding of the present study was the
U-shaped distribution of the doctors' intention to pre-
scribe HT. Indeed, given the recommendation regarding
HT by some of the professional societies at the time this
study was conducted [44-47], one could have expected a
skewed distribution towards a more positive physicians'
intention to prescribe HT. This U-shaped distribution of
the doctors' intention to prescribe HT is in line with the
results of a previous study published in 1986, long before
HT was thought to be benefiting the cardiovascular sys-
tem. Interestingly, in this study published in 1986, doc-
tors were shown to act decisively when facing decisions
about HT [14]. Facing twelve clinical vignettes, most of
the fifty doctors enrolled in this study tended to act deci-
sively (prescribe HT or not) although the decision analysis
model had recommended a "toss-up" strategy (uncertain
decision) 60% of the time. The authors concluded that
"doctors ought to carefully re-examine their practice pat-
terns in light of their beliefs and opinions." [14]. This con-
clusion would still hold true two decades later. It suggests
that it is possible that physicians' intention to prescribe
HT and its determinants could be stable overtime.BMC Medical Informatics and Decision Making 2005, 5:31 http://www.biomedcentral.com/1472-6947/5/31
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This U-shaped distribution of the doctors' behavioural
intention regarding HT was in sharp contrast with the
results from two other studies that applied the theory of
planned behaviour to predict middle-aged women inten-
tion to use HT at menopause in Québec. These two studies
were conducted in the same period as the present study
was. In both these studies, the distribution of the inten-
tion to use HT was normal. In other words, while most
women appeared to be undecided about adopting HT,
physicians from the same geographic area appeared to be
decided about either prescribing HT or not. Again, these
results emphasise the need for future interventions that
will facilitate the active participation of women in the
decision-making leading to a prescription of HT.
Strengths and limitations of the study results
A major strength of this study is its use of theory to
improve understanding of the decision-making of doctors
leading to a prescription of HT. Therefore, the use of an
existing theoretical framework helped standardize the
presentation of the many factors that are likely to influ-
ence this prescription behaviour [48]. It has the potential
to: 1) facilitate the comparison between similar studies, 2)
make it possible to carry out a systematic review in this
area, and 3) contribute to the elaboration of a theoretical
base for understanding the decision-making leading to a
prescription behaviour. Other researchers might want to
follow this process.
In spite of these strengths, this study has limitations. First,
given that this study was conducted before the results of
the Women's Health Initiative trial were publicized [1],
we can not guarantee that its results would still be appli-
cable. The decline in postmenopausal HT use was most
marked for standard-dose of the estrogenic agent used in
the Women's Health Initiative trial [9]. However, contrary
to this trend, prescription for lower-dose formulations
increased modestly [9]. Moreover, in France, results from
the Women's Health Initiative trial have been criticized by
French professional societies based on the fact that treat-
ments used were different in France – mainly transdermal
estrogens – and that French postmenopausal women were
at lower vascular risk than those of the Women's Health
Initiative trial [49]. In United States, studies of women
younger than those enrolled in this trial and lower HT
doses with intermediate endpoints are beginning [50].
Therefore, given the clinical vignette that was used in this
study (there was no explicit dosage and formulae of HT),
we believe that this study results might still be applicable
to the current situation.
Second, doctors were asked to indicate their intention to
prescribe HT to a specific but hypothetical woman. The
clinical vignette that was used was succinct and did not
provide all the clinical information that some doctors
might have desired. However, a large proportion of doc-
tors who participated in this study expressed a specific
intention to prescribe HT or not, perhaps indicating that
they felt they had enough information to make a decision.
Moreover, clinical vignettes are known to be a valid and
comprehensive method to asses the process of care pro-
vided in actual clinical practice [51]. Therefore, we believe
our results can improve our understanding of the prescrip-
tion of HT in this specific clinical situation.
Last, although this study was designed to draw a repre-
sentative sample of GPs and gynaecologists from each
country, we can not guarantee that our results apply to the
whole population of GPs and gynaecologists from which
our sample was drawn. The response rate that was
obtained in both countries compared well with other
studies that have applied the theory of planned behaviour
to study doctors' behaviour [24,25,52]. Nonetheless, this
response rate as well as the ratio of GPs and gynaecolo-
gists limits the inference of our results to the whole popu-
lation of doctors. However, it does not limit the inference
of the overall regression model for this group of respond-
ents. Thus, the results of this study provide a valuable con-
tribution to the theory base of doctors' prescription
behaviour.
Conclusion
Despite its limitations, the present study still has clinical
and research implications. Geographic variations in
health care delivery remain a challenge [39]. This study
provides empirical data on the significant contribution of
moral norm in the decision-making leading to a prescrip-
tion of HT by doctors and possibly in other contexts of
preference-sensitive care [39]. This is preoccupying
because it is contrary to on-going efforts to incorporate
the best available scientific evidences as well as the
patients' views in health [53], one of the cornerstones of
improving the quality of health care [54]. Therefore, it
would be important in this type of clinical situation to
provide guidance to doctors on how to support active par-
ticipation of patients in the decision-making process.
This study should be useful to those interested in the
application of social cognitive models in studying doctors'
behaviour. Given the lack of theorization in the area of
health care professional practice [20,55], this study results
improve the knowledge base in translation of evidence as
well as the knowledge base of physicians' decision-mak-
ing in context of preference-sensitive care [39]. It provides
insight about the contribution of moral norm and role
beliefs above variables provided by the theory of planned
behaviour to explain doctors' behaviour and perhaps, var-
iation in health care delivery. In future studies applying
the theory of planned behaviour, these constructs should
be tested with other type of doctors' behaviours. ThisBMC Medical Informatics and Decision Making 2005, 5:31 http://www.biomedcentral.com/1472-6947/5/31
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study should also be useful in improving our understand-
ing of cross-cultural variations in medical practices by
focusing on theory-based psychosocial variables. Lastly,
this study points to possible pathways through which a
given implementation strategy is likely to be effective in
modifying doctors' prescription of HT. Researchers inter-
ested in elaborating interventions to modify this prescrip-
tion behaviour could use this study results accordingly.
Competing interests
The author(s) declare that they have no competing
interests.
Authors' contributions
France Legare, Gaston Godin, Sylvie Dodin and Virginie
Ringa designed the study with assistance from Joanna
Norton. Data were collected and managed by Lucile Tur-
cot and France Legare. Data were analyzed by France
Legare, Gaston Godin and Lucile Turcot. France Legare
wrote the report. All authors contributed to the revision of
various drafts and approved the final version of the sub-
mitted manuscript.
Acknowledgements
We are indebted to the doctors from France and Quebec who participated 
to this study. This research was supported by an unrestricted grant from 
Fournier Pharma and peer-reviewed by a scientific committee from the 
Fonds de la recherche du Quebec (FRSQ). Dr. Legare is a new clinical sci-
entist who is supported by the FRSQ. Dr. Godin is Tier 1 Canada Research 
Chair in Health Related Behaviour, Université Laval. Dr Dodin holds the 
Chaire Andree et Lucie Chagnon pour une approche integrée en santé, 
Université Laval.
References
1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C,
Stefanick ML, Jackson RD, Beresford SAA, Howard BV, Johnson KC,
Morley Kotchen J, Ockene J: Risks and Benefits of Estrogen Plus
Progestin in Healthy Postmenopausal Women. Principal
Results From the Women's Health Initiative Randomized
Controlled Trial.  JAMA-Express 2002, 288:321-333.
2. Wilkes HC, Meade TW: Hormone replacement therapy in gen-
eral practice: a survey of doctors in the MRC's general prac-
tice research framework.  BMJ 1991, 302:1317-1320.
3. Ghali WA, Freund KM, Boss RD, Ryan CA, Moskowitz MA: Meno-
pausal Hormone Therappy: Physician Awareness of Patient
Attitudes.  Am J Med 1997, 103:3-10.
4. Andersson K, Tonnes Pedersen A, Mattsson LA, Milsom I: Swedish
gynecologists' and general practitioners' views on the cli-
macteric period: knowledge, attitudes and management
strategies.  Acta Obstet Gynecol Scand 1998, 77:909-916.
5. Collaborative Group on Hormonal Factors in Breast Cancer: Breast
cancer and hormone replacement therapy: collaborative
reanalysis of data from 51 epidemiological studies of 52,705
women with breast cancer and 108,411 women without
breast cancer. Collaborative Group on Hormonal Factors in
Breast Cancer.  Lancet 1997, 350:1047-1059.
6. Beral V: Breast cancer and hormone-replacement therapy in
the Million Women Study.  Lancet 2003, 362:419-427.
7. Kaufert PA, Lock M: Medicalization of women's third age.  J Psy-
chosom Obstet Gynaecol 1997, 18:81-86.
8. IMS Health Canada: Canadian Compuscript Audit [database].  .
9. Majumdar SR, Almasi EA, Stafford RS: Promotion and prescribing
of hormone therapy after report of harm by the Women's
Health Initiative.  Jama 2004, 292:1983-1988.
10. Maclennan AH, Broadbent JL, Lester S, Moore V: Oral oestrogen
and combined oestrogen/progestogen therapy versus pla-
cebo for hot flushes.  Cochrane Database Syst Rev 2004:CD002978.
11. Brown JP, Josse RG: 2002 clinical practice guidelines for the
diagnosis and management of osteoporosis in Canada.  Cmaj
2002, 167:S1-34.
12. Banks E, Beral V, Reeves G, Balkwill A, Barnes I: Fracture incidence
in relation to the pattern of use of hormone therapy in post-
menopausal women.  Jama 2004, 291:2212-2220.
13. Mort EA: Clinical decision-making in the face of scientific
uncertainty: hormone replacement therapy as an example.
J Fam Pract 1996, 42:147-151.
14. Elstein AS, Holzman GB, Ravitch MM, Metheny WA, Holmes MM,
Hoppe RB, Rothert ML, Rovner DR: Comparison of Physicians'
Decisions Regarding Estrogen Replacement Therapy for
Menopausal Women and Decisions Derived from aDecision
Analytic Model.  The American Journal of Medicine 1986, 80:246-258.
15. Obermeyer CM, Sahel A, Hajji N, Schulein M: Physicians' percep-
tions of menopause and prescribing practices in Morocco.  Int
J Gynaecol Obstet 2001, 73:47-55.
16. Levy BT, Ritchie JM, Smith E, Gray T, Zhang W: Physician specialty
is significantly associated with hormone replacement ther-
apy use.  Obstet Gynecol 2003, 101:114-122.
17. Nilsen ST, Pedersen AT, Moen MH, Milsom I, Mattsson LA, Iversen
OE, Larsen PM, Andersson K: Knowledge, attitudes and man-
agement strategies in Scandinavia concerning hormone
replacement therapy: a comparison between gynecologists
in Denmark, Norway and Sweden.  Maturitas 2001, 39:83-90.
18. Newton KM, LaCroix AZ, Buist DS, Anderson LA, Delaney K: What
factors account for hormone replacement therapy prescrib-
ing frequency?  Maturitas 2001, 39:1-10.
19. Hovi SL, Karttunen T, Karro H, Hemminki E: Comparison of Esto-
nian and Finnish physicians' opinions of menopause and hor-
mone therapy.  Maturitas 2004, 49:107-113.
20. Grol R, Grimshaw J: From best evidence to best practice: effec-
tive implementation of change in patients' care.  Lancet 2003,
362:1225-1230.
21. Ajzen I: Attitudes, personality and behavior.  In Mapping social
psychology Edited by: Keynes M. , Open University Press; 1988:xiv, 175
p.. 
22. Millstein SG: Utility of the theories of reasoned action and
planned behavior for predicting physician behavior: a pro-
spective analysis.  Health Psychology 1996, 15:398-402.
23. Walker AE, Grimshaw JM, Armstrong EM: Salient beliefs and
intentions to prescribe antibiotics for patients with a sore
throat.  Br J Health Psychol 2001, 6:347-360.
24. Gagnon MP, Godin G, Gagne C, Fortin JP, Lamothe L, Reinharz D,
Cloutier A: An adaptation of the theory of interpersonal
behaviour to the study of telemedicine adoption by
physicians.  Int J Med Inform 2003, 71:103-115.
25. Liabsuetrakul T, Chongsuvivatwong V, Lumbiganon P, Lindmark G:
Obstetricians' attitudes, subjective norms, perceived con-
trols, and intentions on antibiotic prophylaxis in caesarean
section.  Soc Sci Med 2003, 57:1665-1674.
26. Gaither CA, Bagozzi RP, Ascione FJ, Kirking DM: The determi-
nants of physician attitudes and subjective norms toward
drug information sources: modification and test of the the-
ory of reasoned action.  Pharm Res 1997, 14:1298-1308.
27. Ajzen I: The Social Psychology of Decision Making.  In Social Psy-
chology: handbook of basic principles Volume Chapter II. Edited by: Hig-
gins ET and Kruglanski AW. New York (NY), Guilford Press;
1996:297-325. 
28. Godin G, Kok G: The theory of planned behavior: a review of
its applications to health-related behaviors.  American Journal of
Health Promotion 1996, 11:87-98.
29. Sheeran P: Intention-behaviour relations: A conceptual and
empirical review.  In European review of social psychology Volume 12.
Edited by: Stroebe W and Hewstone M. Chichester, UK, WIley;
2002:1-36. 
30. Triandis HC: Interpersonal Behavior.  Edited by: Daigen V.
Monterey, Ca., Brooks/Cole Publishing Company A Division of
Wadsworth Publishing Company, Inc.; 1977:329. 
31. Légaré F, Godin G, Guilbert , Laperrière L, Dodin S: Determinants
of the intention to adopt hormone replacement therapy
among premenopausal women.  Maturitas 2000, 34:211-218.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medical Informatics and Decision Making 2005, 5:31 http://www.biomedcentral.com/1472-6947/5/31
Page 12 of 12
(page number not for citation purposes)
32. Légaré F, Godin G, Dodin S, Turcot-Lemay L, Laperrière L: Adher-
ence to hormone replacement therapy: a longitudinal study
using the theory of planned behaviour.  Psychology and Health
2003, 18:351-371.
33. Dillman DA: Mail and Telephone Surveys: The Total Design
Method.  New York, Wiley-Interscience; 1978:375. 
34. National Cancer Institute: Breast Cancer Risk Assessment Tool.
[http://bcra.nci.nih.gov].
35. Gagné C, Godin G: The Theory of Planned Behavior: Some
Measurement Issues Concerning Belief-Based Variables.
Journal of Applied Social Psychology 2000, 30:2173-2193.
36. French DP, Hankins M: The expectancy-value muddle in the
theory of planned behaviour - and some proposed solutions.
Br J Health Psychol 2003, 8:37-55.
37. Ringa V, Legare F, Dodin S, Norton J, Godin G, Breart G: Hormone
therapy prescription among physicians in France and
Quebec.  Menopause 2004, 11:89-97.
38. Hoffmann M, Lindh-Astrand L, Ahlner J, Hammar M, Kjellgren KI:
Hormone replacement therapy in the menopause. Struc-
ture and content of risk talk.  Maturitas 2005, 50:8-18.
39. Wennberg JE: Unwarranted variations in healthcare delivery:
implications for academic medical centres.  Bmj 2002,
325:961-964.
40. Towle A, Godolphin W: Framework for teaching and learning
informed shared decision making [see comments].  Bmj 1999,
319:766-771.
41. Durand G: Introduction générale à la bioéthique. Histoire,
concepts et outils.  Première edition. , Editions Fides Cerf;
1999:565. 
42. Charles C, Gafni A, Whelan T: Shared decision-making in the
medical encounter: what does it mean? (or it takes at least
two to tango).  Soc Sci Med 1997, 44:681-692.
43. Armstrong D: Clinical autonomy, individual and collective: the
problem of changing doctors' behaviour.  Soc Sci Med 2002,
55:1771-1777.
44. Schiff I, Rebar RW, Cramer JA, Gerbino PP, Hammond CB, Jeffe DB,
Motheral BR, Rothert M, Sarrel PM: Achieving Long-Term Con-
tinuance of Menopausal ERT/HRT: Consensus Opinion of
The North American Menopause Society.  Menopause; The Jour-
nal of The North American Menopause Society 1998, 5:69-76.
45. NAMS: A decision tree for the use of estrogen replacement
therapy or hormone replacement therapy in postmenopau-
sal women: consensus opinion of the North American Men-
opause Society.  Menopause 2000:76-86.
46. NAMS: Clinical challenges of perimenopause: consensus opin-
ion of the North American Menopause Society.  Menopause
2000, 7:5-13.
47. SOGC: The Canadian Consensus Conference on Menopause
and Osteoporosis.  Toronto, Ontario, Ribosome Communications
Inc.; 1998:64. 
48. Saillour-Glenisson F, Michel P: [Individual and collective facilita-
tors and barriers to the use of clinical guidelines by physi-
cians: a literature review.  Revue Épidémiologique de Santé Publique
2003, 51:65-80.
49. Gayet-Ageron A, Amamra N, Ringa V, Tainturier V, Berr C, Clavel-
Chapelon F, Delcourt C, Delmas PD, Ducimetiere P, Schott AM:
Estimated numbers of postmenopausal women treated by
hormone therapy in France.  Maturitas 2005.
50. Barrett-Connor E, Grady D, Stefanick ML: The rise and fall of
menopausal hormone therapy.  Annu Rev Public Health 2005,
26:115-140.
51. Peabody JW, Luck J, Glassman P, Dresselhaus TR, Lee M: Compari-
son of vignettes, standardized patients, and chart abstrac-
tion: a prospective validation study of 3 methods for
measuring quality.  Jama 2000, 283:1715-1722.
52. Hu PJH, Chau PYK: Physician Acceptance of Telemedicine
Technology: An Empirical Investigation.  Top Health Inform
Manage 1999, 19:20-35.
53. Walter FM, Britten N: Patients' understanding of risk: a qualita-
tive study of decision-making about the menopause and hor-
mone replacement therapy in general practice.  Fam Pract
2002, 19:579-586.
54. Wensing M, Elwyn G: Methods for incorporating patients' views
in health care.  Bmj 2003, 326:877-879.
55. Eccles M, Grimshaw J, Walker A, Johnston M, Pitts N: Changing the
behavior of healthcare professionals: the use of theory in
promoting the uptake of research findings.  J Clin Epidemiol
2005, 58:107-112.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1472-6947/5/31/prepub